Elekta Ab Class B · OMXSTO:EKTA_B
Elekta Ab Class B — Carnegie Healthcare Seminar 2017
23 slides from Elekta Ab Class B's conference presentation, Mar 16, 2017
Slide 1: Elekta Carnegie Healthcare Seminar 2017
Elekta Carnegie Healthcare Seminar 2017 Richard Hausmann, President and CEO March 16, 2017
Slide 2: Elekta – global leader in radiation therapy
Elekta – global leader in radiation therapy • One of the two major global companies in radiation therapy • Active on 120 markets globally • ~40% global market share; leader in Asia Pacific and Europe • Over 1 M treatments per year • 3,700 installed systems • 3,600 employees worldwide • Net sales SEK
Slide 3: Radiation therapy – underlying growth potential
Radiation therapy – underlying growth potential Lack of capacity • At least 10,000 additional linacs are required to meet current needs* Underlying growing need Innovation enable • New cancer cases to grow from 15 M per year to 24 M by 2035 broader usage • Additional cancer types • Increased recurre
Slide 4: Oncology Informatics Portfolio and Treatment Solutions
EMR PARTICAL RADIATION ONCOLOGY & MEDICAL THERAPY ONCOLOGY INFORMATICS Treatment pathway centric REGISTRY Vendor & therapy agnostic Localized to markets SERVICES & SUPPORT MOSAIQ MOSAIQ MOSAIQ METRIC/LGK Oncology specific EMR Oncology Analytics Image & Plan Review Cancer Registries SURGERY Oncology
Slide 5: Elekta's revenue base (rolling 12 months)
Elekta’s revenue base (rolling 12 months) Oncology Informatics Oncology informatics Linear 16% Accelerators* Linear 16% Brachy- accelerators* Brachy therepy* 62% 9% 9% Therapy* 62% 13% Neuroscience* 13% Neuroscience* 5 | Focus where it matters *Including treatment planning software and service
Slide 6: Market position in linear accelerators
Market position in linear accelerators NEW ORDERS* NEW SOCKETS** INSTALLED BASE Other Other 10% Other 12% 23% Elekta Elekta 41% Elekta 24% 47% Varian Varian Varian 49% 41% 53% *Order intake of linear accelerators last twelve months **New radiation therapy departments or expansion by new bunker 6 | F
Slide 7: Focus areas: 1. Innovation 2. Transformation
Focus areas: 1. Innovation 2. Transformation 7
Slide 8: Focus areas: Innovation and Transformation
Focus areas: 1. Innovation 2. Transformation “To create the possible we have to constantly try the impossible” Hermann Hesse 8
Slide 9: The innovation opportunities for radiotherapy
The innovation opportunities for radiotherapy More outcome and focus where it matters Image guidance Workflow Automation • High field MR as the • Integrated and automated • Big data applications ultimate soft tissue workflows on treatment imaging tool units • Decision support with self learning • Ad
Slide 10: Wrapping high dose tight to target is sufficient in static situations
Wrapping high dose as tight as possible to a target is sufficient in static situations… 10 | Focus where it matters
Slide 11: Targets often move; advanced imaging helps reduce margins
…but targets often move and only advanced imaging helps reduce margins and further limit dose to healthy tissue… 11 | Focus where it matters
Slide 12: Seamless on-line plan adaptation is vital
…and for day-to-day changes of shape and position, seamless and on-line plan adaptation is vital. ONLINE ADAPTIVE • Diagnostic Imaging • Dose Calculation • Dose Adjustment • Repositioning • Plan Adaptation
Slide 13: MR-Linac
MR-Linac Cone Beam IGRT (New) (Today) Esophagus MR-Linac Bladder Brings together the capability of high-field diagnostic MR imaging, the highest standard of precision radiation therapy delivery and sophisticated adaptive workflow software for the first time. Rectal tumor
Slide 14: How to navigate in today's RT-world
How to navigate in todays RT-world Plan dose Adaptive navigation provides actual information to decide how to best reach destination Anatomical changes IGRT added navigation Patient moves Faster cars Arrive at actual delivered dose 14 | Focus where it matters 14
Slide 15: 12 MR-linac customers to date
7 consortium sites 5 commercial systems 12 MR-linac customers to date Ambition: Launch in 75 orders H2 calendar until 2019 year 2017 Note: all in line with local regulatory requirements
Slide 16: Focus areas: 1. Innovation 2. Transformation
Focus areas: 1. Innovation 2. Transformation 16
Slide 17: Transformation for profitable growth on track
Kan vi göra denna Transformation for snyggare? profitable growth on track Objectives • Improve processes and structure • Reduce cost and restore profitability • Strengthen cash flow and reduce working capital • Improve customer experience and drive excellence in product development
Slide 18: Ambition is to improve EBITA margin to >20%
Ambition is to improve EBITA margin to >20% Margin development* (illustrative) Transformation program targets EBITA margin of >20% by 2017/18 47% 46% 43% 41% 41% 40% Cost reductions of Net working capital Produce-to-order 23% 22% SEK 700**M to sales below process. One-off 20% 14% 15% 16% with full e
Slide 19: Net working capital at 1% of net sales
Net working capital at 1% of net sales* KEY WORKING CAPITAL ASSETS 4 000 NET WORKING CAPITAL as % of SALES Accounts 15% 3 000 receivables 2 000 Accrued 10% income 1 000 5% Inventories 0 1,0% Q3 15/16 Q4 15/16 Q1 16/17 Q2 16/17 Q3 16/17 0% 1601AC 1604AC 1607AC 1610AC 1701AC KEY WORKING CAPITAL LIABIL
Slide 20: Q3 update: strong order intake and cash flow
Q3 update: strong order intake and cash flow › Order growth in Q3 +34% and +11% YTD › Growth in all product areas › Net Sales in Q3: +5% in SEK and +1% in local currency › EBITA margin in Q3: at 12% (13) › Rolling 12-months EBITA margin improved to 16 percent or +2 percentage points since last year
Slide 21: Improved backlog position going into Q4
Improved backlog position going into Q4 Q3 2015/16 Q3 2016/17 (SEK bn) (SEK bn) 21.9 18.0 3.5 2.7 7.0 7.6 Order Revenue Expected Order Revenue Expected backlog YTD revenue from backlog YTD revenue backlog in from backlog Q4 in Q4 21 | Focus where it matters
Slide 22: Unique position, strong product offering, transformation on track
UNIQUE POSITION in long-term growing market STRONG PRODUCT OFFERING and leading R&D portfolio TRANSFORMATION ON TRACK for operational excellence and profitable growth
Slide 23: Focus where it matters.
Focus where it matters. t. Ad CyElekta